Strategic Analysis of the European Markets for Theranostics

Published by: Frost & Sullivan

Published: May. 26, 2009 - 53 Pages

Table of Contents

Please note that Table of Contents numbering has been standardized and may not match numbering within the publication.

1: Introduction

2: Research Scope and Methodology

2.1: Scope

2.2: Methodology

3: Benefits of Theranostics

4: Test Categories of Theranostics

5: Stakeholder Analysis

6: The Pharma-Diagnostics Convergence

7: Unveiling the Opportunities

8: Value Addition to Pharmaceutical Industry

8.1: The Impact of Convergence

9: Application in Drug Development Process

10: Industry Challenges and Recommendations

11: Key Market Dynamics: Market Drivers

12: Key Market Dynamics: Market Restraints

13: Disease Areas: Overview

14: Case Study - Cambridge Theranostics Ltd

14.1: Noteworthy Innovation in the Cardio-theranostics Sector

15: Neuro-disorders

16: Special Focus: Oncology

17: Why Cancer is at the Center Stage of Theranostics?

18: Role of Theranostics in Cancer Management

19: Breast Cancer

20: Herceptin: Poster-Child of Theranostics

21: Recent Advances in Cancer Theranostics

Table 1: Theranostics Market: Recent Advances in Cancer Theranostics (Europe), 2008

22: Competitive Overview

23: Competitive Factor Analysis

24: Key Competitive Areas

25: Drugs with Companion Diagnostic Tests

Table 2: Theranostics Market: Drugs with Companion Diagnostic Tests (Europe), 2008

26: Regulatory Scenario: An Overview

27: Initiatives by FDA and EMEA

27.1: FDA: Critical Path Initiative

27.2: EMEA: Innovative Medicines Initiative

28: Pharmacogenomics and EMEA

28.1: Efforts to Familarise with Pharmacogenomics

28.2: Activities Associated with Drug Discovery and Development

28.3: Pharmacogenomics in Clinical Practice

28.4: Drug-diagnostic Co-development

29: EMEA: Path towards Pharmacogenomics (PGx)

30: Strategic Viewpoint: SWOT Analysis for Theranostics Market

31: Conclusion: Past, Present and the Future

32: The Future of Pharmacogenomics

33: Decision Support Databases

Table 3: Goverment Healthcare Expenditure (Bn USD)

Table 4: Pharmaceuical R&D Expenditure as a percentage of Pharmaceutical market

Table 5: Number of Physicians (000)

Table 6: Breast Cancer Mortality

34: Database of Key Industry Participants

Abstract

This Frost & Sullivan research service titled Strategic Analysis of the European Markets for Theranostics provides a strategic analysis of the theranostics market in Europe. This research service focuses on the current scenario in the market, its dynamics and the regulatory scenario. It also includes competitive analysis and strategic recommendations for current industry challenges. In this research, Frost & Sullivan's expert analysts thoroughly examine the key applications of theranostics in the following disease areas: cancer, cardiovascular diseases and neuro disorders.

Market Overview

Theranostics Ushers in Personalised Medicine in Europe - A Milestone in the Drug Therapy Process

Theranostics, an emerging field in clinical diagnostics, focuses on developing specific analysis to predict the most suitable drug for a patient as well as assesses the efficacy of the drug. It uses molecular assays to determine the optimum dose of drugs for a patient, ushering in personalised medicine. Although significant awareness has been created about personalised medicine, its full potential is yet to be tapped. Factors such as cost and regulatory timelines are the key hurdles that need to be addressed at the moment. "The emergence of personalised medicine with the help of theranostics is a milestone in the drug therapy process," says the analyst of this research. "Its targeted approach enables the prescription of only those drugs that are linked to a specific biomarker assay, thereby benefiting the physicians, patients, insurance, and regulatory agencies." The availability of advanced technology to support research projects has resulted in novel therapeutics. As more biomarkers are discovered and their importance known, the need for specific theranostic assays is likely to increase.

However, the high cost associated with genetic testing for the identification of biomarkers poses a challenge to the success of theranostics. The uncertainty associated with the clinical utility of biomarkers discovered will negatively impact the return-on-investment (ROI). "Theranostics is a well understood science, yet pharmaceutical companies have been late adopters," says the analyst. "It is rare to see large pharma and diagnostic companies branding themselves as theranostic companies."

Improved cooperation between drug and diagnostic companies will enhance the success of theranostics. The commercialisation of theranostics will be possible by effective communication with the physicians to understand its penetration in the market. "Companies focusing on theranostics with already licensed drugs can play a key role in reaching out to larger pharmaceutical companies," concludes the analyst. "Pharmaceutical companies should be aware of the importance of linking diagnostics to its drug development process."

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.